Announced details
Treatment of pain associated with endometriosis; dysmenorrhea; adjustment of the timing for initiating controlled ovarian stimulation in assisted reproductive technology
Our subsidiary
ASKA Pharmaceutical Co., Ltd. Headquarters: Minato-ku, Tokyo. Representative Director and President: Yamaguchi Sota (山口惣大). Other details: Not disclosed.
Minato-ku, Tokyo (ASKA Pharmaceutical Co., Ltd. headquarters)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Droechiflex Combination Tablets® “ASKA” |
| Counterparty overview | ASKA Pharmaceutical Co., Ltd. Headquarters: Minato-ku, Tokyo. Representative Director and President: Yamaguchi Sota (山口惣大). Other details: Not disclosed. |
| Relationship with the Company | Our subsidiary |
| Launch date | Scheduled for launch following listing on the National Health Insurance drug price list (specific date: Not disclosed) |
| Applicable area | Treatment of pain associated with endometriosis; dysmenorrhea; adjustment of the timing for initiating controlled ovarian stimulation in assisted reproductive technology |
| Location | Minato-ku, Tokyo (ASKA Pharmaceutical Co., Ltd. headquarters) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ASKA Pharmaceutical stated that the approval will enable it to expand its portfolio of obstetrics and gynecology products as it works toward becoming a specialty healthcare company.